Unthinkable scenes were seen yesterday at the United States Capitol, after supporters of president Donald Trump broke into the building during a session in which members of Congress were expected to confirm Trump’s loss in this year’s presidential election to his Democrat rival, Joe Biden. At least one person died during the ensuing clashes with the police and local security officers. Brazilian president Jair Bolsonaro halted all purchases of syringes due to a spike in prices, precisely at the moment in which the prospect of vaccines against COVID-19 arriving in the country is increasing. Meanwhile, researchers from the University of São Paulo have been surprised after identifying 17 mutations of the new strain of the novel coronavirus first identified in the United Kingdom, which had two cases already detected in Brazil. The government of Germany has decided to extend a national lockdown and implement measures such as a mandatory quarantine and testing on visitors from abro
Share this article
Share this article
ResearchAndMarkets.com s offering.
After analyzing the global surgical site infection control market in detail, the publisher has concluded that the industry would display an upward trend, with a CAGR of 5.95% in terms of revenue in the forecasting years of 2021 to 2028.
Factors such as the adoption of best practices for infection prevention & control and growth in the elderly population are majorly fueling the growth of this industry. However, the lack of proper infection control programs is hindering this growth process. Moreover, the growing adoption of outpatient procedures and enhanced usage of medical disposable items are hampering the market growth even further. On the bright side, the growing incidence of surgical procedures and a significant increase in the occurrence of complications from HAIs are creating avenues for the growth of the surgical site infection control market.
PRESS RELEASE
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
Agreement provides a framework for future clinical trials, manufacturing, sales and marketing, and distribution within the National Health Service of Brazil
Bio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one of the world s most respected public health research institutions
Abingdon, Oxon, UK, 5 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, today announces that it has signed a collaboration and development agreement with the Institute of Technology on Immunobiologicals (Bio-Manguinhos) of the Oswaldo Cruz Foundation (Fiocruz) in Brazil to develop a COVID-19 vaccine usi
News Category Global Banking & Finance Reviews
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
PRESS RELEASE
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
Agreement provides a framework for future clinical trials, manufacturing, sales and marketing, and distribution within the National Health Service of Brazil
Bio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one of the world’s most respected public health research institutions
Abingdon, Oxon, UK, 5 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, today announces that it has signed a collaboration an
Coronavirus: Le bilan en Amérique latine s alourdit à plus de 500 000 décès latribune.fr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from latribune.fr Daily Mail and Mail on Sunday newspapers.